ALNY | Alnylam Pharmaceuticals, Inc.

Index	-	P/E	-	EPS (ttm)	-8.70	Insider Own	0.10%	Shs Outstand	124.11M	Perf Week	-1.47%
Market Cap	23.15B	Forward P/E	-	EPS next Y	-2.47	Insider Trans	-27.07%	Shs Float	122.39M	Perf Month	-9.55%
Income	-1064.90M	PEG	-	EPS next Q	-1.53	Inst Own	97.20%	Short Float / Ratio	4.18% / 7.06	Perf Quarter	4.47%
Sales	1.14B	P/S	20.25	EPS this Y	-29.10%	Inst Trans	0.99%	Short Interest	5.12M	Perf Half Y	-17.51%
Book/sh	-2.09	P/B	-	EPS next Y	59.90%	ROA	-30.90%	Target Price	249.95	Perf Year	36.89%
Cash/sh	17.07	P/C	11.18	EPS next 5Y	-	ROE	-	52W Range	122.57 - 242.97	Perf YTD	-19.70%
Dividend	-	P/FCF	-	EPS past 5Y	-11.40%	ROI	-100.80%	52W High	-21.46%	Beta	0.48
Dividend %	-	Quick Ratio	3.60	Sales past 5Y	63.10%	Gross Margin	83.60%	52W Low	55.69%	ATR	5.17
Employees	2002	Current Ratio	3.80	Sales Q/Q	49.70%	Oper. Margin	-75.60%	RSI (14)	45.54	Volatility	1.84% 2.72%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	29.70%	Profit Margin	-93.10%	Rel Volume	0.51	Prev Close	190.43
Shortable	Yes	LT Debt/Eq	-	Earnings	May 04 BMO	Payout	-	Avg Volume	725.59K	Price	190.83
Recom	1.90	SMA20	-0.80%	SMA50	-4.05%	SMA200	-8.46%	Volume	373,397	Change	0.21%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178
Mar-01-22	Initiated	Citigroup	Buy	$223
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy	$170
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$181 → $208
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$144 → $225
Nov-22-21	Upgrade	Goldman	Neutral → Buy	$273
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform	$200
Oct-04-21	Upgrade	UBS	Neutral → Buy	$141 → $215
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral	$45 → $47
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral	$162
Feb-12-21	Reiterated	H.C. Wainwright	Buy	$225 → $235
Feb-12-21	Downgrade	Citigroup	Buy → Neutral	$170 → $175

Show Previous Ratings

Jun-05-23 04:00PM	Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-01-23 06:22AM	Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares (Simply Wall St.)
May-26-23 04:55PM	Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines (Reuters)
May-22-23 12:01PM	Alnylam (ALNY) Reports Positive Results From APOLLO-B Study (Zacks)
May-20-23 10:50AM	Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (Business Wire)
02:59PM	Loading…
May-09-23 02:59PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 03:44PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
12:35PM	Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues (Zacks)
06:03AM	Alnylam Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-04-23 09:15AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Alnylam: Q1 Earnings Snapshot (AP Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
May-03-23 04:00PM	Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference (Business Wire)
08:00AM	Alnylam Issues 2022 Corporate Responsibility Report (Business Wire)
Apr-27-23 01:52PM	Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says (Benzinga)
10:02AM	Loading…
10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-26-23 08:18PM	UPDATE 1-Second judge says US not liable in Moderna COVID-19 vaccine patent case (Reuters)
06:59PM	Second judge says US not liable in Moderna COVID-19 vaccine patent case (Reuters)
06:53PM	Second judge says US not liable in Moderna COVID-19 vaccine patent case (Reuters)
04:05PM	Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimers Disease and Cerebral Amyloid Angiopathy (GlobeNewswire)
04:05PM	Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimers Disease and Cerebral Amyloid Angiopathy (Business Wire)
Apr-24-23 03:55PM	3 Pharma Stocks That Could See a Surge in Demand in 2023 (InvestorPlace)
Apr-20-23 10:03AM	Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results (Business Wire)
Mar-30-23 11:30AM	Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report? (Zacks)
Mar-21-23 01:30PM	Alnylam CEO Yvonne Greenstreet sees growing the company as 'a wonderful challenge' (American City Business Journals)
03:31AM	Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength? (Zacks)
Mar-13-23 03:29PM	3 Growth Stocks That Could Disrupt the Healthcare Industry (InvestorPlace)
Mar-09-23 07:00AM	Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics (PR Newswire)
07:00AM	Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics (CNW Group)
07:00AM	Loading…
Mar-08-23 07:00AM	Alnylam Announces Appointment of Peter Kellogg to Board of Directors (Business Wire)
Mar-01-23 08:00AM	Alnylam to Webcast Presentations at Upcoming March Investor Conferences (Business Wire)
Feb-28-23 10:01AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-25-23 11:44AM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript (Insider Monkey)
08:00AM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Feb-24-23 08:58AM	Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues (Zacks)
Feb-23-23 09:15AM	Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity (Business Wire)
02:31AM	Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio? (Insider Monkey)
Feb-22-23 10:28AM	Should You Buy Alnylam Pharmaceuticals (ALNY) Ahead of Earnings? (Zacks)
08:46AM	Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More (Zacks)
Feb-21-23 08:00AM	Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire) -10.29%
Feb-16-23 10:01AM	Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
06:30AM	Feng Zhang launches $193M startup with Alnylam vets at the helm (American City Business Journals)
Feb-13-23 12:49PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-07-23 07:48PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-02-23 10:00AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Jan-13-23 07:32PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Jan-09-23 01:22PM	Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22 (Zacks)
Jan-08-23 06:00PM	Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates (Business Wire)
Jan-06-23 05:39AM	3 Growth Stocks That Could Rocket Higher in 2023 (Motley Fool)
Jan-05-23 04:00PM	Alnylam Announces Updates to its Board of Directors (Business Wire)
Jan-04-23 12:20PM	VERA Dips Despite Positive Data From IgA Nephropathy Study (Zacks)
Jan-03-23 07:33PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
04:00PM	Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-22 05:41AM	The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug (American City Business Journals)
Dec-21-22 08:00AM	Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes (Business Wire)
Dec-15-22 08:00AM	Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day (Business Wire)
Dec-13-22 08:29AM	Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 44% Undervaluation? (Simply Wall St.)
Dec-09-22 11:30AM	Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound? (Zacks)
11:21AM	Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy (Zacks)
Dec-08-22 04:00PM	Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
07:00AM	Alnylam to Webcast Virtual R&D Day (Business Wire)
Dec-01-22 11:31AM	Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report? (Zacks)
07:00AM	Alnylam Ranks #1 on Boston Globes Top Places to Work List for 2022 (Business Wire)
Nov-09-22 08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Nov-02-22 11:45AM	Investors ignore increasing losses at Alnylam Pharmaceuticals (NASDAQ:ALNY) as stock jumps 7.3% this past week (Simply Wall St.)
Oct-31-22 08:49AM	Top 10 Stock Picks of Eli Casdins Casdin Capital (Insider Monkey)
Oct-27-22 02:00PM	Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year (Business Wire)
01:45PM	Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program (Benzinga)
11:00AM	Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3 (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity (Business Wire)
Oct-26-22 02:48PM	Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More (Zacks)
Oct-25-22 10:01AM	Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-20-22 10:02AM	Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline (Zacks)
Oct-18-22 12:56PM	Heres Why Baron Health Care Fund Added Alnylam Pharmaceuticals (ALNY) to its Portfolio (Insider Monkey)
Oct-14-22 08:34AM	Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-13-22 08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results (Business Wire)
Oct-11-22 05:52AM	3 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Oct-07-22 12:12PM	Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion (Zacks)
10:56AM	Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease (Benzinga)
Oct-06-22 08:30PM	Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 (Business Wire)
Oct-03-22 06:08AM	Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval (Benzinga)
Sep-30-22 02:00PM	Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting (Business Wire)
Sep-22-22 12:17PM	Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks)
04:00PM	Alnylam Announces New Management Appointments (Business Wire)
Sep-20-22 02:45PM	Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program (Benzinga)
07:00AM	Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy (Business Wire)
Sep-19-22 08:00AM	Alnylam to Host Ninth Annual "RNAi Roundtable" Webcast Series (Business Wire)
Sep-16-22 11:29AM	Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study (Zacks)
Sep-15-22 04:22PM	Something Unusual Is Happening Right Now With Biotech Stocks (Investor's Business Daily)
09:41AM	Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers (Benzinga)
07:00AM	Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (PR Newswire)
07:00AM	Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (Business Wire)
Sep-13-22 08:00AM	Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022 (Business Wire)
06:00AM	Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes (Business Wire)
Sep-12-22 06:45AM	Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes (Business Wire) -5.05%

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Pushkal	CMO & EVP Dev & Med Affairs	Apr 28	Sale	199.02	2,455	488,595	4,345	Apr 28 05:54 PM
Greenstreet Yvonne	Chief Executive Officer	Apr 27	Sale	194.59	7,615	1,481,811	30,332	Apr 28 05:55 PM
Vaishnaw Akshay	President	Apr 27	Sale	194.59	2,392	465,464	17,890	Apr 28 05:54 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Apr 27	Sale	194.59	1,839	357,855	6,800	Apr 28 05:54 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Apr 27	Sale	194.59	1,476	287,215	1,801	Apr 28 05:55 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Apr 27	Sale	194.59	977	190,113	11,706	Apr 28 05:55 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Apr 06	Sale	210.00	3,500	735,000	0	Apr 10 04:29 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03	Option Exercise	96.45	5,000	482,250	22,417	Mar 07 04:07 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03	Sale	200.00	18,072	3,614,400	4,345	Mar 07 04:07 PM
SCHULMAN AMY W	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:13 PM
HAMBURG MARGARET A	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:12 PM
PYOTT DAVID E I	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:13 PM
Ausiello Dennis A	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:11 PM
Fanucci Marsha	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:11 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 03	Sale	232.14	3,424	794,854	0	Feb 03 05:45 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 02	Sale	226.01	1,675	378,563	3,500	Feb 03 05:46 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 02	Sale	226.01	1,601	361,839	3,424	Feb 03 05:45 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 01	Option Exercise	0.00	5,025	0	5,025	Feb 03 05:45 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 01	Option Exercise	0.00	5,175	0	5,175	Feb 03 05:46 PM
Vaishnaw Akshay	President	Dec 05	Option Exercise	59.05	5,079	299,938	23,425	Dec 07 04:09 PM
Ausiello Dennis A	Director	Nov 21	Option Exercise	71.09	22,500	1,599,638	22,500	Nov 23 04:05 PM
Ausiello Dennis A	Director	Nov 21	Sale	220.00	22,500	4,950,000	0	Nov 23 04:05 PM
SHARP PHILLIP A	Director	Aug 15	Option Exercise	33.77	33,670	1,137,066	33,670	Aug 17 04:07 PM
SHARP PHILLIP A	Director	Aug 15	Sale	230.49	33,670	7,760,736	0	Aug 17 04:07 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 05	Sale	218.16	1,841	401,630	0	Aug 05 04:15 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 03	Sale	210.00	1,754	368,340	3,629	Aug 05 04:15 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jul 05	Sale	150.00	1,754	263,100	1,754	Jul 07 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY | Alnylam Pharmaceuticals, Inc.

Upgrade your FINVIZ experience